IRWD Q3 2020 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$603M

Q3 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$103M-21.1% YoY

Gross Profit

$82M79.0% margin

Operating Income

$46M44.1% margin

Net Income

$34M33.3% margin

EPS (Diluted)

$0.21

QoQ Revenue Growth

+15.7%

Cash Flow

Operating Cash Flow

$54M

Free Cash Flow

$54M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$492M

Total Liabilities

$486M

Stockholders' Equity

$6M

Cash & Equivalents

$309M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$103M	$131M	-21.1%
Gross Profit	$82M	$131M	-37.4%
Operating Income	$46M	$66M	-30.8%
Net Income	$34M	$21M	+66.7%

Revenue Segments

Collaborative Arrangement Promotion Agreement

$1M33%

Collaborative Arrangement Co Promotion Agreement

$1M33%

License And Service

$900,00027%

Royalty

$200,0006%

Geographic Segments

North America

$721,00024%

Canada And Mexico

$700,00023%

Europe And Other

$510,00017%

J

$500,00016%

Europe

$500,00016%

China Hong Kong And Macau

$100,0003%